Current role
Biotechnology · Healthcare
CEO, Board Member
2015-01-01–present
David J. Mazzo
Board Member
Lisata Therapeutics, Inc. (LSTA)Equibles does not estimate personal net worth.
Get an email with a short summary when Lisata Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get LSTA alertsAbout David J. Mazzo
David J. Mazzo is recorded as CEO at Lisata Therapeutics, Inc. (LSTA) since September 15, 2022 and Board Member at Lisata Therapeutics, Inc. (LSTA) since January 1, 2015. The newest filing on record that lists David J. Mazzo as CEO at Lisata Therapeutics, Inc. (LSTA) is dated October 19, 2026. The newest filing on record that lists David J. Mazzo as Board Member at Lisata Therapeutics, Inc. (LSTA) is dated April 25, 2025. Lisata Therapeutics, Inc. reported in an 8-K filed September 15, 2022 that David J. Mazzo was appointed Chief Executive Officer, effective September 15, 2022. The proxy statement of Lisata Therapeutics, Inc. reports total compensation of $1,147,359 for David J. Mazzo in fiscal 2025, including a base salary of $711,729. Disclosed compensation is on record for 8 fiscal years. Lisata Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Lisata Therapeutics, Inc. includes David J. Mazzo, Ph.D. (CEO), Gregory Brown (Chairman), Gregory Brown, M.D. (Chairman) and 7 others.
“Following the closing of the merger, David J. Mazzo, Ph.D., current President and Chief Executive Officer of Caladrius will continue as the Chief Executive Officer of Lisata”
Affiliation history
-
Current
2022-09-15–present
Last confirmed October 19, 2026
-
Current
2015-01-01–present
Last confirmed April 25, 2025
Company network
Leadership on record at Lisata Therapeutics, Inc.
- David J. Mazzo, Ph.D. CEO
- Gregory Brown Chairman
- Gregory Brown, M.D. Chairman
- Dr. Josh Lehrer COO
- Josh Lehrer COO
- Josh Lehrer, M.D., M.Phil., FACC COO
- Tariq Imam General Counsel
- James Nisco Chief Accounting Officer
- Anne Whitaker Board Member
- CLASS I Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Lisata Therapeutics, Inc. (LSTA) | Chief Executive Officer | $711,729 | $1,147,359 |
| 2024 | Lisata Therapeutics, Inc. (LSTA) | Chief Executive Officer | $702,969 | $1,691,174 |
| 2023 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $675,931 | $1,408,382 |
| 2022 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $650,441 | $1,929,933 |
| 2021 | Lisata Therapeutics, Inc. (LSTA) | Chief Executive Officer | $631,495 | $1,335,216 |
| 2020 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $613,102 | $1,435,031 |
| 2019 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $596,693 | $1,539,651 |
| 2018 | Lisata Therapeutics, Inc. (LSTA) | President and Chief Executive Officer | $593,796 | $1,892,242 |